KISUNLA Gets FDA Nod for Patent Extension Timeline
Published Date: 7/14/2025
Notice
Summary
The FDA has officially set the review period for KISUNLA, a human biological product, so its patent can be extended. This helps the company get more time to protect their invention before others can copy it. If you’re involved in drug development or patents, this means important deadlines and opportunities are coming up.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA OKs Patent Extension Window
If you own or work for the company that makes KISUNLA (a human biological product), the FDA has set the regulatory review period so the company can apply to the U.S. Patent and Trademark Office to extend a patent that claims this product. This action makes a patent-extension opportunity official and starts the deadlines tied to seeking that extension.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in